| Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2013: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2012: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2011: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Research Abstract |
To establish pharmacologicaly-directed tailor-made chemotherapy for leukemia, the mechanisms of action and resistance of clofarabine were investigated using two newly developed clofarabine-resistant leukemic cell lines.
The resistant cell lines exhibited reduced clofarabine triphosphate production due to decreased mRNA levels of 3 cell membrane transporters and low protein levels of 2 kinases. The cell lines also showed increased Bcl-2 protein levels, suggestive of antiapoptosis. A cytarabine-resisntant leukemic cell line that had been previously develped showed reduction in only one transporter and one kinase, and 1/10 reduced cytarabine triphosphate. This cell line still possessed the sensitivity to clofarabine, which was atttibutable to the capacity to produce clofarabine triphosphate.
Thus, pharmacologically-directed tailor-made chemotherapy will be established using surrogate markers (intracellular triphosphate production and Bcl-2 exression) to overcome resistance of leukemia.
|
